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A B S T R A C T
Neurodegenerative diseases are linked to the accumulation of speciﬁc protein aggregates, suggesting an intimate
connection between injured brain and loss of proteostasis. Proteostasis refers to all the processes by which cells
control the abundance and folding of the proteome thanks to a wide network that integrates the regulation of
signaling pathways, gene expression and protein degradation systems. This review attempts to summarize the
most relevant ﬁndings about the transcriptional modulation of proteostasis exerted by the transcription factor
NRF2 (nuclear factor (erythroid-derived 2)-like 2). NRF2 has been classically considered as the master
regulator of the antioxidant cell response, although it is currently emerging as a key component of the
transduction machinery to maintain proteostasis. As we will discuss, NRF2 could be envisioned as a hub that
compiles emergency signals derived from misfolded protein accumulation in order to build a coordinated and
perdurable transcriptional response. This is achieved by functions of NRF2 related to the control of genes
involved in the maintenance of the endoplasmic reticulum physiology, the proteasome and autophagy.
1. Introduction
Nuclear Factor (erythroid-derived 2)-like 2 (NRF2) is a basic-
leucine-zipper protein considered nowadays as a master regulator of
cellular homeostasis. It controls the basal and stress-inducible expres-
sion of over 250 genes that share in common a cis-acting enhancer
termed the antioxidant response element (ARE) [1–5]. These genes
participate in phase I, II and III detoxiﬁcation reactions, glutathione
and peroxiredoxin/thioredoxin metabolism, NADPH production
through the pentose phosphate pathway and malic enzyme, fatty acid
oxidation, iron metabolism, and proteostasis [6]. Given these wide
cytoprotective functions, it is possible that a single pharmacological hit
in NRF2 might mitigate the eﬀect of the main culprits of chronic
diseases, including oxidative, inﬂammatory and proteotoxic stress. The
role of NRF2 in the modulation of the antioxidant defense and
resolution of inﬂammation have been addressed in numerous studies
(reviewed in [7]). Here, we will focus on its role in proteostasis, i.e., the
homeostatic control of protein synthesis, folding, traﬃcking and
degradation. Examples will be provided in the context of neurodegen-
erative diseases.
http://dx.doi.org/10.1016/j.redox.2017.01.006
Received 7 December 2016; Received in revised form 4 January 2017; Accepted 5 January 2017
⁎ Corresponding author at: Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Investigación Sanitaria La Paz (IdiPaz),
Instituto de Investigaciones Biomédicas Alberto Sols UAM-CSIC, Madrid, Spain.
E-mail address: airojo@iib.uam.es (A.I. Rojo).
Abbreviations: α-SYN, alpha synuclein; β-TrCP, β-transducin repeat containing E3 ubiquitin protein ligase; Aβ, amyloid beta; AD, Alzheimer's disease; ALS, amyotrophic lateral
sclerosis; AMPK, AMP-activated protein kinase; ARE, antioxidant response element; ASK1, apoptosis-signal-regulating kinase 1; ATF-6, activating transcription factor 6; APP, amyloid
precursor protein; CG islands, cytosine guanine islands; ChIP, chromatin immunoprecipitation; CJD, Creutzfeldt Jakob disease; CSF, cerebrospinal ﬂuid; D3T, 1,2-dithiole-3-thione;
DMF, dimethyl fumarate; ER, endoplasmic reticulum; ERO1, sulfhydryl oxidase endoplasmic oxidoreductin 1; FOXO, forkhead box; GCLC, glutamate-cysteine ligase catalytic subunit;
GCLM, glutamate-cysteine ligase modulatory subunit; GFP, green ﬂuorescent protein; GLT-1, glutamate transporter 1; GPX, glutathione peroxidase; GR, GSR, glutathione reductase;
GSH, glutathione (c-glutamyl-l-cysteinylglycine); GSK-3, glycogen synthase kinase-3; GSSG, glutathione disulﬁde; GST, glutathione S-transferase; HD, Huntington's disease; Htt,
huntingtin; HMOX1, heme oxygenase-1; IRE1, inositol-requiring kinase 1; JNK, c-Jun N-terminal kinase; KEAP1, kelch-like ECH-associated protein 1; MAPKs, mitogen-activated
protein kinases; MPTP, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine; MEF, mouse embryonic ﬁbroblasts; mTOR, mammalian target of rapamycin; NQO1, NAD(P)H:quinone
oxidoreductase 1; NRF1, nuclear factor (erythroid-derived 2)-like 1; NRF2, nuclear factor (erythroid-derived 2)-like 2; LIR, LC3 interacting region; PERK, pancreatic ER eIF2α kinase;
PD, Parkinson's disease; PDI, protein disulﬁde isomerase; PI3K, phosphatidyl inositol-3 kinase; PKA, protein kinase A; PKC, protein kinase C; PrP, prionic protein; PS1, presenilin 1;
PRX, peroxiredoxin; ROS, reactive oxygen species; SFN, sulforaphane; SOD1, Cu/Zn-superoxide dismutase 1; TAK1, TGF-β-activated kinase 1; TFEB, transcription factor EB; UBA,
ubiquitin associated domain; UPS, ubiquitin proteasome system; UPR, unfolded protein response; XBP1, X box-binding protein 1; γ-GCL, γ -glutamylcysteine synthetase; γGS, γ
-glutamate cysteine synthetase; γGT, γ -glutamyl transpeptidase
Redox Biology 11 (2017) 543–553
Available online 10 January 2017
2213-2317/ © 2017 The Authors. Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
MARK
2. Loss of proteostasis inﬂuences NRF2 activity in
neurodegenerative diseases
A general hallmark of neurodegenerative diseases is the occurrence
of aberrant aggregation of some proteins. Thus, misfolded protein
aggregates of α-synuclein (α-SYN) are found in Parkinson's disease
(PD), β-amyloid (Aβ) plaques and hyper-phosphorylated TAU neuroﬁ-
brillary tangles in Alzheimer's disease (AD), huntingtin (Htt) in
Huntington's disease (HD), superoxide dismutase 1 (SOD1) and TAR
DNA binding protein 43 (TDP-43) in amyotrophic lateral sclerosis
(ALS), prion protein (PrP) in spongiform encephalopathies, etc.
Protein aggregates can have an impact on several cellular pathways,
which in turn may aﬀect NRF2 levels and activity.
2.1. Diﬀerent layers of regulation tightly control NRF2 activity
Under physiological conditions, cells exhibit low NRF2 protein
levels because of its rapid turnover. In response to diﬀerent stimuli,
NRF2 protein is accumulated, enters the nucleus and increases the
transcription of ARE-containing genes. Therefore, management of
NRF2 protein levels is a key point that should integrate positive and
negative input signals. As we will discuss further, NRF2 is activated by
diverse overlapping mechanisms to orchestrate a rapid and eﬃcient
response but on the other hand NRF2 could be inhibited, probably in a
second phase, in order to switch oﬀ its response.
From the classic point of view, activation of NRF2 has been
considered as a consequence of the cellular response to oxidant or
electrophilic compounds. In this regard, the ubiquitin E3 ligase adaptor
Kelch-like ECH-associated protein 1 (KEAP1) plays a crucial role.
Molecular details will be further addressed in Section 4.1. In brief,
KEAP1 acts as a redox sensor due to critical cysteine residues leading to
NRF2 ubiquitination and proteasomal degradation. In addition to this
classic modulation, NRF2 is profoundly regulated by signaling events.
Indeed, diﬀerent kinases have been shown to phosphorylate and
regulate NRF2. For instance, NRF2 can be phosphorylated by mitogen
activated protein kinases (MAPKs), although its contribution to NRF2
activity remains unclear [8–11]. PKA kinase as well as some PKC
isozymes [12], CK2 [13] or Fyn [14] phosphorylate NRF2 modifying its
stability. Previous work from our group reported that glycogen
synthase kinse-3β (GSK-3β) inhibits NRF2 by nuclear exclusion and
proteasomal degradation [15,25–30]. The molecular details will be
discussed in the Section 4.1. Furthermore, NRF2 is submitted to other
types of regulation. For instance, NRF2 acetylation by CBP/p300
increases its activity [17], while it is inhibited by miR153, miR27a,
miR142-5p, and miR144 [16], or by methylation of cytosine-guanine
(CG) islands within the NRF2 promoter [18].
2.2. Impact of protein aggregates on NRF2 regulatory mechanisms
In this section we will focus in how accumulation of misfolded
protein could impact NRF2 activity providing some of the pathways
mentioned above as illustrative examples. Firstly, we need to consider
that protein accumulation has been tightly linked with oxidative
damage. Indeed, misfolded protein accumulation and aggregation
induce abnormal production of reactive oxygen species (ROS) from
mitochondria and other sources [19]. As mentioned above, ROS will
modify redox-sensitive cysteines of KEAP1 leading to the release,
stabilization and nuclear localization of NRF2.
Regarding proteinopathies, an example of dysregulated signaling
events that may aﬀect NRF2 is provided by the hyperactivation of GSK-
3β in AD. GSK-3β, also known as TAU kinase, participates in the
phosphorylation of this microtubule-associated protein, resulting in its
aggregation, formation of neuroﬁbrillary tangles and interruption of
axonal transport (reviewed in [20]). On the other hand, GSK-3β
dramatically reduces NRF2 levels and activity as mentioned above.
Although not widely accepted, the amyloid cascade proposes that toxic
Aβ oligomers increase GSK-3β activity together with TAU hyper-
phosphorylation and neuron death [21,22]. There are diﬀerent models
to explain how Aβ favors GSK3-β activity. For instance, Aβ binds to the
insulin receptor and inhibits PI3K and AKT signaling pathways, which
are crucial to maintain GSK-3β inactivated by phosphorylation at its N-
terminal Ser9 residue [23]. On the other hand, extracellular Aβ
interacts with Frizzled receptors, blocking WNT signaling [24] and
again resulting in release of active GSK-3β. In summary, Aβ accumula-
tion leads to abnormal hyperactivation of GSK-3β, thus impairing an
appropriate NRF2 response.
As discussed in the following section, misfolded proteins lead to
activation of PERK and MAPKs, which in turn up-regulate NRF2
[31,8–11]. Moreover, dysregulated CBP/p300 activity has been re-
ported in several proteinopathies [32] and a global decrease in DNA
methylation in AD brains was also shown [33], therefore providing
grounds to explore the relevance of these ﬁndings in NRF2 regulation.
We and others have observed in necropsies of PD and AD patients
an increase in NRF2 protein levels and some of its targets, such as
heme oxygenase 1 (HMOX1), NADPH quinone oxidase 1 (NQO1), p62,
etc., both by immunoblot and by immunohistochemistry [34–39]. The
up-regulation of NRF2 in these diseases is interpreted as an unsuccess-
ful attempt of the diseased brain to recover homeostatic values.
However, another study indicated that NRF2 is predominantly loca-
lized in the cytoplasm of AD hippocampal neurons, suggesting reduced
NRF2 transcriptional activity in the brain [40]. It is conceivable that
the disparity of these observations is related to changes in the factors
that control NRF2 along the progressive stages of neurodegeneration.
Three major systems contribute to proteostasis, namely the un-
folded protein response (UPR), the ubiquitin proteasome system (UPS)
and autophagy. Next, we present evidence to envision NRF2 as a hub
connecting emergency signals activated by protein aggregates with the
protein derivative machinery.
3. NRF2 participates in the unfolded protein response (UPR)
3.1. NRF2 activation in response to the UPR
Oxidative protein folding in the ER is driven by a number of distinct
pathways, the most conserved of which involves the protein disulﬁde-
isomerase (PDI) and the sulfhydryl oxidase endoplasmic oxidoreductin
1 (ERO1α and ERO1β in mammals) as disulﬁde donor. Brieﬂy, PDI
catalyzes the formation and breakage of disulﬁde bonds between
cysteine residues within proteins, as they fold, due to the reduction
and oxidation of its own cysteine aminoacids. PDI is recycled by the
action of the housekeeping enzyme ERO1, which reintroduces disulﬁde
bonds into PDI [41]. Molecular oxygen is the terminal electron
acceptor of ERO1, which generates stoichiometric amounts of hydro-
gen peroxide for every disulﬁde bond produced [42]. Peroxidases
(PRX4) and glutathione peroxidases (GPX7 and GPX8) are key
enzymes to reduce hydrogen peroxide in the ER. When this oxido-
reductive system does not work properly, abnormal accumulation of
misfolded proteins occurs in the ER and a set of signals named the
unfolded protein response (UPR) is transmitted to the cytoplasm and
nucleus to reestablish the ER homeostasis [43]. Three membrane-
associated proteins have been identiﬁed for sensing ER stress in
eukaryotes: activating transcription factor 6 (ATF6), pancreatic ER
eIF2α kinase (PERK, also double-stranded RNA-activated protein
kinase-like ER kinase), and inositol-requiring kinase1 (IRE1). The
luminal domain of each sensor is bound to a 78 kDa chaperone termed
glucose-regulated protein (GRP78/BIP). BIP dissociates upon ER
stress to bind unfolded proteins, leading to the activation of the three
sensors [44].
NRF2 and its homologue NRF1, also related to the antioxidant
response, participate in the transduction of the UPR to the nucleus. In
the case of NRF1, this protein is located at the ER membrane and
undergoes nuclear translocation upon deglycosylation or cleavage.
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Then, UPR activation leads to the processing of NRF1 and nuclear
accumulation of the resulting fragment in the nuclear compartment.
However, the ability to transactivate ARE-containing genes of this
NRF1 fragment is still under discussion [45].
Glover-Cutter and co-workers showed activation of the NRF2
orthologue of C. elegans, SKN-1, with diﬀerent ER stressors.
Increased SKN-1 expression was dependent on diﬀerent UPR media-
tors, including IRE1 or PERK worm orthologues [46]. In PERK-
deﬁcient cells, impaired protein synthesis leads to accumulation of
endogenous peroxides and subsequent apoptosis [47]. The eﬀector
used by PERK to protect the ER from these peroxides might be NRF2,
since it has been reported that PERK phosphorylates NRF2 at Ser40,
thus preventing its degradation by KEAP1 [31]. The induction of ASK1
is also likely to play a role in this route through the TRAF2-mediated
kinase action of IRE1 [48]. Although the role of MAPKs in the
regulation of NRF2 is still controversial, it was recently suggested that
the IRE1-TRAF2-ASK1-JNK pathway might activate NRF2 [49]
(Fig. 1). Interestingly, in C. elegans and human cells, new evidence
suggests that cysteine sulfenylation of IRE1 kinase at its activation loop
inhibits IRE1-mediated UPR and initiates a p38 antioxidant response
driven by NRF2. The data suggest that IRE1 has an ancient function as
a cytoplasmic sentinel that activates p38 and NRF2 [50].
Many studies on the induction of the UPR have been conducted
with the inhibitor of protein glycosylation tunicamycin. NRF2 appears
to be essential for prevention of tunicamycin-induced apoptotic cell
death [31] and its activation under these conditions is driven by the
autophagic degradation of KEAP1 [51]. Accordingly, shRNA-mediated
silencing of NRF2 expression in βTC-6 cells, a murine insulinoma β-
cell line, signiﬁcantly increased tunicamycin-induced cytotoxicity and
led to an increase in the expression of the pro-apoptotic ER stress
marker CHOP10. On the other hand, NRF2 activation by 1,2-dithiole-
3-thione (D3T) reduced tunicamycin cytotoxicity and attenuated the
expression of CHOP10 and PERK [52]. Interestingly, olfactory neurons
submitted to systemic application of tunicamycin increased NRF2 in
parallel with other UPR-members such as CHOP, BIP, XBP1 [53].
These results have been extended to in vivo studies, as lateral
ventricular infusion of tunicamycin in rats induced expression of
PERK and NRF2 in the hippocampus accompanied by signiﬁcant
cognitive deﬁcits, increased TAU phosphorylation and Aβ42 deposits
[54].
3.2. NRF2 up-regulates key genes for the maintenance of the ER
physiology
The ER lumen needs an abundant supply of GSH from the cytosol
in order to maintain disulﬁde chemistry. NRF2 modulates crucial
enzymes of the GSH metabolism in the brain, such as cystine/
glutamate transport, γ-glutamate cysteine synthetase (γ-GS), gluta-
mate-cysteine ligase catalytic and modulator subunits (GCLC and
GCLM), glutathione reductase (GR) and glutathione peroxidase
(GPX) (reviewed in [55]). The relevance of NRF2 in the maintenance
of GSH in the ER is supported by the ﬁnding that pharmacological or
genetic activation of NRF2 results in increased GSH synthesis via
GCLC/GCLM, while inhibiting the expression of these enzymes by
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Fig. 1. Regulation of NRF2 by the UPR. Accumulation of unfolded or misfolded proteins inside the endoplasmic reticulum can initiate the unfolded protein response (UPR). First,
the chaperone BIP is released from the intraluminal domain of the ER sensors IRE1 and PERK to bind unfolded/misfolded proteins. This enables dimerization and trans-auto-
phosphorylation of their cytosolic domains. PERK activation results in direct NRF2 phosphorylation at Ser40, leading to NRF2 translocation to the nucleus and activation of target
genes. IRE1 activation induces the recruitment of TRAF2 followed by ASK1 and JNK phosphorylation and activation. As JNK has been reported to phosphorylate and activate NRF2, it is
reasonable to think that IRE1 activation would lead to increased NRF2 activity.
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NRF2-knockdown caused an accumulation of damaged proteins within
the ER leading to the UPR activation [56].
In C. elegans several components of the UPR target genes regulated
by SKN-1, including Ire1, Xbp1 and Atf6. Although NRF2 up-regulates
the expression of several peroxidase (PRX) and glutathione peroxidase
(GPX) genes in mammals (reviewed in [57]), only GPX8 is a bona ﬁde
ER-localized enzyme, harboring the KDEL retrieval signal [58]. Loss of
GPX8 causes UPR activation, leakage of ERO1α-derived hydrogen
peroxide to the cytosol and cell death. Hydrogen peroxide derived from
ERO1α activity cannot diﬀuse from the ER to the cytosol owing to the
concerted action of GPX8 and PRX4 [59]. In this regard, an analysis of
the antioxidant defense pathway-gene expression array using RNA
from wild type and NRF2-null mice tissue, revealed that the expression
of GPX8 was down-regulated in the absence of NRF2 [60]. In line with
this, transcriptome analysis from patient samples suﬀering from
myeloproliferative neoplasms, polycythemia or myeloﬁbrosis, diseases
also associate with oxidative stress and low-grade chronic inﬂamma-
tion, show lower expression levels of both NRF2 and GPX8 compared
with control subjects [61]. There are not yet studies that speciﬁcally
involve GPX8 in human brain protection but a transcriptome analysis
in mice indicates a compensatory GPX8 increase in response to the
Parkinsonian toxin MPTP [62].
3.3. Impact of NRF2 on the UPR dysregulation in neurodegenerative
diseases
Malfunction of PDI enzymes and chronic activation of the UPR
might subsequently initiate or accelerate neurodegeneration. Disease-
aﬀected neurons, animal models of neurodegenerative disease as well
as post-mortem human tissues evidenced up-regulation of several
UPR-markers in most of these disorders. The alteration of PDI/UPR
pathway in neurodegenerative diseases has been nicely reviewed in
[63] but the following highlights from brain post-mortem samples
should be considered. PDI levels are increased in tangle-bearing
neurons and in Lewy Bodies of AD and PD patients, respectively
[64,65]. PDI and ERP57 are up-regulated in CSF from ALS patients
and in brains from CJD subjects [66–68]. BIP, PERK, IRE1 and ATF6
are elevated in samples from patients with AD, PD or ALS [69–71,67].
BIP, CHOP and XBP1 are elevated in post-mortem brain samples from
HD [72,73]. Moreover, up-regulation of ERP57, GRP94 and BIP was
found in cortex tissues from CJD patients [74]. Altogether, this
evidence reveals that the accumulation of misfolded proteins in the
brain parenchyma leads to a deleterious and chronic activation of the
UPR. Interestingly, there is a recent study linking activation of NRF2
by PERK in early AD. In this study, the authors analyzed whether
oxidative stress mediated changes in NRF2 and the UPR may
constitute early events in AD pathogenesis by using human peripheral
blood cells and an AD transgenic mouse model at diﬀerent disease
stages. Increased oxidative stress and increased pSer40-NRF2 were
observed in human peripheral blood mononuclear cells isolated from
individuals with mild cognitive impairment. Moreover, they reported
impaired ER calcium homeostasis and up-regulated ER-stress markers
in these cells from individuals with mild cognitive impairment and
mild AD [75].
4. Mutual regulation of NRF2 and the ubiquitin proteasome
system (UPS)
4.1. The UPS modulates NRF2 protein levels
The UPS participates in the degradation of damaged or misfolded
proteins and controls the levels of key regulatory molecules in the
cytosol and the nucleus. The central core of this system is a large
multisubunit enzyme that contains a proteolytic active complex named
20S. The 20S core proteasome degrades unfolded proteins, but binding
to diﬀerent regulatory protein complexes changes its substrate speci-
ﬁcity and activity. For instance, the addition of one or two 19S
regulatory subunits to the 20S core constitutes the 26S proteasome
and changes its speciﬁcity towards native folded proteins [76,77].
Proteasomal degradation needs covalent binding of ubiquitin.
Conjugation of ubiquitin proceeds via a three-step cascade mechanism.
First, the ubiquitin-activating enzyme E1 activates ubiquitin in an ATP-
requiring reaction. Then, one E2 enzyme (ubiquitin-carrier protein or
ubiquitin-conjugating enzyme) transfers the activated ubiquitin from
E1 to the substrate that is speciﬁcally bound to a member of the
ubiquitin-protein ligase family, named E3. Although the exact fate of
the ubiquitinated-protein will depend on the nature of the ubiquitin
chain, this process generally results in the degradation by the 26S
proteasome [78].
The E3-ligase KEAP1 is the best known inhibitor of NRF2. The
mechanism of KEAP1 regulation elegantly explains how NRF2 levels
adjust to oxidant ﬂuctuations. Under basal conditions, newly synthe-
sized NRF2 is grabbed by the homodimer KEAP1, which binds one
NRF2 molecule at two amino acid sequences with low (aspartate,
leucine, glycine; DLG) and high (glutamate, threonine, glycine, gluta-
mate; ETGE) aﬃnity. The interaction with KEAP1 aids to present
NRF2 to the CULLIN3/RBX1 protein complex, resulting in its ubiqui-
tination and subsequent proteasomal degradation. However, redox
modiﬁcation of KEAP1 impedes presentation of NRF2 to the UPS
represented by CULLIN3/RBX1. As a result, newly synthetized NRF2
escapes KEAP1-dependent degradation, accumulates in the nucleus
and activates ARE-containing genes [79–82].
The E3-ligase adaptor β-TrCP is also a homodimer that participates
in the signaling events related to the phosphorylation of NRF2 by GSK-
3β. This kinase phosphorylates speciﬁc serine residues of NRF2
(aspartate, serine, glycine, isoleucine serine; DSGIS) to create a
degradation domain that is then recognized by β-TrCP and tagged for
proteasome degradation by a CULLIN1/RBX1 complex. The identiﬁca-
tion of the speciﬁc amino acids that are phosphorylated by GSK-3β in
this degron was conducted by a combination of site-directed mutagen-
esis of the Neh6 domain, 2D-gel electrophoresis [15,26] and mass
spectroscopy [83]. Consequently, inhibition of GSK-3β by highly
selective drugs or siRNAs against GSK-3 isoforms resulted in an
increase in NRF2 protein levels. Similar results were found with
siRNAs against β-TrCP isoforms 1 and 2. Stabilization of NRF2
following GSK-3β inhibition occurred in KEAP1-deﬁcient mouse
embryo ﬁbroblasts and in an ectopically expressed NRF2 deletion
mutant lacking the critical ETGE residues for high-aﬃnity binding to
KEAP1, further demonstrating a KEAP1-independent regulation.
In the context of neurodegenerative diseases, we can envision the
modulation of NRF2 by the UPS in two diﬀerent ways. On the one
hand, the KEAP1 system would sense redox imbalance derived from
misfolded protein accumulation, while GSK-3/β-TrCP axis would act as
an active participant in signaling transduction altered by loss of
proteostasis (Fig. 2).
4.2. NRF2 increases UPS activity through the transcriptional control
of proteasome subunits
NRF2 up-regulates the expression of several proteasome subunits,
thus protecting the cell from the accumulation of toxic proteins. Twenty
proteasome- and ubiquitination-related genes appear to be regulated
by NRF2, according to a wide microarray analysis from liver RNA that
was set up with the NRF2 inducer D3T [84]. In a posterior study, the
same authors evidenced that the expression of most subunits of the 26S
proteasome were enhanced up to three-fold in livers from mice treated
with D3T. Subunit protein levels and proteasome activity were
coordinately increased. However, no induction was seen in mice where
the transcription factor NRF2 was disrupted. Promoter activity of the
PSMB5 (20S) proteasome subunit increased with either NRF2 over-
expression or treatment with activators in mouse embryonic ﬁbro-
blasts, and AREs were identiﬁed in the proximal promoter of PSMB5
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[85]. Pharmacological activation of NRF2 resulted in elevated expres-
sion levels of representative proteasome subunits (PSMA3, PSMA6,
PSMB1 and PSMB5) only in non-senescent human ﬁbroblasts contain-
ing functional NRF2 [86]. NRF2 activation during adaptation to
oxidative stress results in high expression of the PSMB1 (20S) and
PA28α subunits (or S11, proteasome regulator) [87]. Moreover, results
from human embryonic stem cells revealed that NRF2 controls the
expression of the proteasome maturation protein (POMP), a protea-
some chaperone, which in turn modulates the proliferation of self-
renewing human embryonic stem cells, three germ layer diﬀerentiation
and cellular reprogramming [88]. All together, these studies indicate
that NRF2 up-regulates the expression of key components of the UPS
and therefore actively contributes to the clearance of proteins that
otherwise would be toxic.
4.3. The NRF2-UPS axis in neurodegenerative diseases
The role of the UPS in neurodegenerative diseases is a ﬁeld of
intensive debate. Initial studies reported decreased proteasome activity
in human necropsies of patients aﬀected from several neurodegenera-
tive diseases. However, other studies employing in vitro and in vivo
approaches found unchanged or even increased proteasome activity
(reviewed in [89]). One possible explanation for this discrepancy is that
the levels of the UPS components might change during disease
progression and in diﬀerent brain regions as is has been suggested
for NRF2-targets.
Despite this controversy, it should be noted that up-regulation of
ARE-containing proteasome genes will reinforce the UPS by increasing
the clearance of toxic proteins in the brain. Indeed, ablation of NRF1,
also modulator of the antioxidant response, in neuronal cells leads to
impaired proteasome activity and neurodegeneration. Chromatin im-
munoprecipitation experiments and transcriptional analysis demon-
strated that PSMB6 is regulated by NRF1. In addition, gene expression
proﬁling led to the identiﬁcation of NRF1 as a key transcriptional
regulator of proteasome genes in neurons, suggesting that perturba-
tions in NRF1 may contribute to the pathogenesis of neurodegenerative
diseases [90]. Interestingly, NRF1 and its long isoform called TCF11
were shown to up-regulate ARE-containing proteasome genes upon
proteasome inhibition in a feedback loop to compensate for reduced
proteolytic activity [91,92].
Regarding NRF2, there is a correlation among reduction of NRF2,
RPT6 (19 S) and PSMB5 (20 S) levels in the midbrain of DJ-1-deﬁcient
mice treated with the neurotoxin paraquat [93]. Moreover, the
naturally-occurring compound sulforaphane (SFN) gives a more robust
image of NRF2 as a crucial modulator of the UPS. In vitro experiments
with murine neuroblastoma Neuro2A cells evidenced an enhanced
expression of the catalytic subunits of the proteasome, as well as its
peptidase activities in response to SFN. This drug protected cells from
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result in NRF2 impaired degradation by the proteasome, accumulation and induction of target genes.
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hydrogen peroxide-mediated cytotoxicity and protein oxidation in a
manner dependent on proteasome function [94]. In addition, Liu and
co-workers employed a reporter mouse to monitor the UPS activity in
response to SFN in the brain. These mice ubiquitously express the
green ﬂuorescence protein (GFP) fused to a constitutive degradation
signal that promotes its rapid degradation by the UPS (GFPu). In
cerebral cortex, SFN reduced the level of GFPu with a parallel increase
in chymotrypsin-like (PSMB5), caspase-like (PSMB2), and trypsin-like
(PSMB1) activities of the 20 S proteasome. In addition, treatment of
Huntington-derived cells with SFN revealed that NRF2 activation
enhanced mHtt degradation and reduced mHtt cytotoxicity [95]. The
major mechanism of SFN action is through induction of NRF2 [96].
The speciﬁc contribution of NRF2 should be addressed employing
NRF2-null systems in further studies.
5. Functional connection between NRF2 and
macroautophagy
5.1. NRF2 protein levels are modulated by the adaptor protein p62
Autophagy refers to the degradation of cytosolic components inside
lysosomes. This process is used for the clearance of long-lived and
misfolded proteins as well as damaged organelles. A direct link between
NRF2 and autophagy was ﬁrst observed in connection with the adaptor
protein p62, also termed SQSTM1 [97–101]. This protein shuttles
ubiquitinated proteins to the proteasomal and lysosomal degradation
machineries and sequesters damaged proteins into aggregates prior to
their degradation. P62 presents an ubiquitin-associated (UBA) domain,
for binding to ubiquitinated proteins, and a LC3-interacting region
(LIR) for integration with the autophagosomal membrane through the
autophagy receptor LC3.
Although the p62-mediated induction of NRF2 and its target genes
was ﬁrst reported in 2007 [102], the molecular mechanism was not
fully understood until the discovery of its interaction with KEAP1
[103,98,99–101]. Komatsu and coworkers identiﬁed a KEAP1 inter-
acting region (KIR) in p62 that bound KEAP1 in the same basic surface
pocket as NRF2 and with a binding aﬃnity similar to the ETGE motif in
NRF2, suggesting competition between p62 and NRF2. The phosphor-
ylation of Ser351 in the KIR motif in p62 (349-DPSTGE-354) was
shown to increase its aﬃnity for KEAP1, competing with NRF2 binding
and allowing its accumulation and transcriptional activation of its
target genes [98,99]. In fact, p62 overexpression led to reduced NRF2
ubiquitination and consequent stabilization as well as induction of its
target genes [104]. Some kinases have been suggested to participate in
p62 phosphorylation. The mammalian target of rapamycin complex 1
(mTORC1) may be implicated, as treatment with the mTOR inhibitor
rapamycin suppressed the phosphorylation of p62 and the down-
regulation of KEAP1 upon arsenite treatment. Recently, it was demon-
strated that TGF-β-activated kinase 1 (TAK1) could also phosphorylate
p62, enhancing KEAP1 degradation and NRF2-up-regulation. The
authors of this study suggest this is a way to regulate cellular redoxtasis
under steady-state conditions, as TAK1-deﬁciency up-regulates ROS in
the absence of any exogenous oxidant in diﬀerent mouse tissues in
parallel with a reduction in NRF2 protein levels [105].
A p62 construct lacking the UBA domain was still capable of
binding KEAP1, implying that the interaction did not depend on
ubiquitinated KEAP1 [101]. However, the p62 homologue in
Drosophila melanogaster, named Ref(2), does not contain a KIR motif
and does not directly interact with DmKEAP1, although it can bind to
ubiquitinated DmKEAP1 through the UBA domain. Moreover,
DmKEAP1 can directly interact with Atg8 (homologue to mammalian
LC3). KEAP1 deﬁciency results in Atg8 and autophagy induction
dependent on the NRF2 orthologue CncC and independent on TFEB/
MITF [106]. The relationship between NRF2 and autophagy seems to
be conserved though, highlighting its functional relevance.
The induction of NRF2 by p62 is the result of both the competition
to bind KEAP1 and degradation of KEAP1 in the lysosome. Silencing of
p62 with siRNA doubled KEAP1 half-life in parallel with a decrease in
KEAP1
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Fig. 3. NRF2 levels are regulated by the adaptor protein p62. The phosphorylation of Ser 351 in the KIR motif of p62 (349-DPSTGE-354) by mTORC1, TAK1 or other kinases
results in increased aﬃnity for binding to KEAP1 due to resemblance to the ETGE motif in NRF2. As a consequence, phosphorylated p62 displaces NRF2 and binds KEAP1. The LIR
motif in p62 enables interaction with LC3 in the autophagosomal membrane, so that p62-KEAP1 complex is eventually degraded in the lysosome. As a consequence NRF2 is able to
accumulate, translocate to the nucleus and increase the transcription of ARE-containing genes, including p62. This regulatory mechanism provides a perdurable NRF2 response, as
KEAP1 has to be newly synthesized in order to inhibit NRF2 activity.
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NRF2 and its target genes [101]. In agreement, ablation of p62
expression evidenced increased levels of KEAP1 compared with wild
type mice. Very relevant, the increment in KEAP1 levels was not
aﬀected by proteasome inhibitors but was reduced under starvation-
inducing autophagy [107]. In fact, KEAP1 is present in mammalian
cells in autophagic vesicles decorated with p62 and LC3 [99,100,103].
All these data suggest that KEAP1 is a substrate of the macroautophagy
machinery, but this issue should be analyzed with more detail because
of the existence of some controversial results. KEAP1 protein levels
were increased in Atg7-null mice, a key eﬀector of macroautophagy
[107], but pharmacological inhibition of macroautophagy with torin1,
E64/pepstatin or baﬁlomycin failed to accumulate KEAP1 [107,100].
Overall, these results suggest that increased p62 levels sequester
KEAP1 into autophagic vacuoles and probably these results in
KEAP1 autophagic degradation allowing NRF2 activation (Fig. 3).
Two diﬀerent studies reported that the sulﬁnic acid reductases
SESTRINS play an important role in this context. SESTRIN 2 interacts
with p62, KEAP1 and RBX1 and facilitates p62-dependent degradation
of KEAP1 and NRF2 activation of target genes [108]. Another study
showed that SESTRIN 2 interacted with ULK1 and p62, promoting
phosphorylation of p62 at Ser403 which facilitated degradation of
cargo proteins including KEAP1 [109].
5.2. Modulation of macroautophagy genes by NRF2
NRF2 regulates the expression of relevant genes for macroauto-
phagy as well as it does for the UPR and the UPS. The ﬁrst evidence
came from studies in which p62 expression was shown to be induced
upon exposure to electrophiles, ROS and nitric oxide [110–112]. The
mechanism of induction was described some years later with the
ﬁnding that p62 contains a functional ARE in its gene promoter [99].
In a recent study, several other functional AREs were found and
validated following bioinformatics analysis and ChIP assays. Moreover,
mouse embryonic ﬁbroblasts and cortical neurons from Nrf2-knockout
mice exhibited reduced p62 expression, which could be rescued with an
NRF2-expressing lentivirus. Similarly, NRF2 deﬁciency reduced p62
levels in injured neurons from mice hippocampus [36]. Therefore, it
has been suggested that NRF2 activation increases p62 levels, resulting
in KEAP1 degradation and favoring further NRF2 stabilization in a
positive feedback loop. This non-canonical mechanism of NRF2
induction requires changes in gene expression and might be a relevant
response to prolonged cellular stress.
The cargo recognition protein NDP52 was shown to be transcrip-
tionally regulated by NRF2. NDP52 works in a similar way to p62,
recognizing ubiquitinated proteins and interacting with LC3 through a
LIR domain, so that cargoes are degraded in lysosomes. Five putative
AREs were found in Ndp52 promoter DNA sequence. Three of them
were identiﬁed with diﬀerent mutant constructs and ChIP assays as
indispensable for NRF2-mediated Ndp52 transcription [113]. Of note,
Ndp52 mRNA levels were reduced in the hippocampus of Nrf2-
knockout mice. One of these sequences was also validated in an
independent study as an NRF2-regulated ARE [36].
However, the role of NRF2 in the modulation of autophagy is not
limited to the induction of these two cargo-recognition proteins. In
order to gain deeper insight in the role of NRF2 in the modulation of
additional autophagy-related genes, our group screened the chromatin
immunoprecipitation database ENCODE for two proteins, MAFK and
BACH1, which bind the NRF2-regulated AREs. Using a script gener-
ated from the JASPAR's consensus ARE sequence, we identiﬁed several
putative AREs in many autophagy genes. Twelve of these sequences
were validated as NRF2 regulated AREs in nine autophagy genes,
whose expression was diminished in mouse embryo ﬁbroblasts of Nrf2-
knockout mice but could be restored by an NRF2-expressing lentivirus.
Our study demonstrated that NRF2 activates the expression of some
genes involved in diﬀerent steps of the autophagic process, including
autophagy initiation (ULK1), cargo recognition (p62 and NDP52),
autophagosome formation (ATG4D, ATG7 and GABARAPL1), elonga-
tion (ATG2B and ATG5), and autolysosome clearance (ATG4D).
Consequently, autophagy ﬂux in response to hydrogen peroxide was
impaired when NRF2 was absent [36].
5.3. Relevance of NRF2-mediated macroautophagy genes expression
in neurodegenerative disorders
Defective autophagy has been shown to play an important role in
several neurodegenerative diseases [114] and ablation of autophagy
leads to neurodegeneration in mice [115,116]. Atg7-knockout mice
revealed that autophagy deﬁciency results in p62 accumulation in
ubiquitin-positive inclusion bodies. KEAP1 was sequestered in these
inclusion bodies, leading to NRF2 stabilization and induction of target
genes [103]. Importantly, excessive accumulation of p62 together with
ubiquitinated proteins has been identiﬁed in neurodegenerative dis-
eases, including AD, PD and ALS [117]. In fact, neurons expressing
high levels of APP or TAU of AD patients also expressed p62 and
nuclear NRF2, suggesting their attempt to degrade intraneuronal
aggregates through autophagy [36].
NRF2 deﬁciency aggravates protein aggregation in the context of
AD. In fact, increased levels of phosphorylated and sarkosyl-insoluble
TAU are found in Nrf2-knockout mice, although no diﬀerence in kinase
or phosphatase activities could be detected comparing with the wild-
type background [113]. Importantly, NDP52 was demonstrated to co-
localize with TAU in murine neurons and direct interaction between
phospho-TAU and NDP52 was shown by co-immunoprecipitation
experiments both in mice and AD samples, pointing to its role in
TAU degradation. Interestingly, silencing of NDP52, p62 or NRF2 in
neurons resulted in increased phospho-TAU [113,118]. Moreover,
increased intraneuronal APP aggregates were found in the hippocam-
pus of APP/PS1ΔE9 mice when NRF2 was absent. This correlated with
altered autophagy markers, including increased phospho-mTOR/
mTOR and phospho-p70S6k/p70S6k ratios (indicative of autophagy
inhibition), augmented levels of pre-cathepsin D and a larger number
of multivesicular bodies [119]. In mice co-expressing human APP
(V717I) and TAU (P301L), NRF2 deﬁciency led to increased levels of
total and phospho-TAU in the insoluble fraction and increased
intraneuronal APP aggregates, together with reduced neuronal levels
of p62, NDP52, ULK1, ATG5 and GABARAPL1. Co-localization
between the adaptor protein p62 and APP or TAU was reduced in
the absence of NRF2 [36]. Overall, these results highlight the im-
portance of NRF2 in neuronal autophagy.
6. Diﬀerent transcription factors act coordinately to
modulate proteostasis
Under steady state conditions, proteostasis is controlled via pro-
tein-protein interactions and post-translational modiﬁcations obtain-
ing a rapid response. However, cellular adaptation requires the
transcriptional regulation of the UPR, UPS and autophagy genes.
Considering that nerve cells are continuously submitted to low-grade
toxic insults, including oxidative and proteotoxic stress, a reinforce-
ment of proteostasis induced by transcriptional modulation might help
preventing brain degeneration.
In the case of the UPR, the activation of each of the three arms will
ﬁnally result in the transcriptional induction of certain genes (reviewed
in [43]). For instance, an ATF6-derived fragment (ATF6f) binds to ER-
stress response elements (ERSE) and induces the expression of several
genes, including XBPI, BIP and CHOP. In addition, PERK signaling
leads to the activation of the transcription factor ATF4, which controls
the expression of multiple UPR-related genes and some others includ-
ing the NRF2 target genes Hmox1 and p62. Finally, IRE1 activation
results in the generation of an active transcription factor, spliced XBP1
(XBP1s), which controls the transcription of genes encoding proteins
involved in protein folding.
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On the other hand, NRF1 was shown to be necessary for protea-
somal gene expression in the brain, as Nrf1-knockout mice exhibited
reduced expression of genes encoding various subunits of the 20S core,
as well the 19S regulatory complex together with impaired proteasomal
function [90]. Both NRF1 and NRF2 bind to ARE sequences in the
promoter regions of its target genes, which suggests they have over-
lapping transcriptional activities, although they diﬀer in their regula-
tory mechanisms and cellular localization [120].
Transcription factors of the Forkhead box O (FOXO) family control
the expression of multiple autophagy-related genes. Similar to what
occurs with NRF2, there are multiple layers of regulation of the activity
of FOXO members, which can be induced upon nutritional or oxidative
stress [121]. Finally, the transcription factor TFEB, considered the
master regulator of lysosomal biogenesis, plays a crucial role in
regulation of autophagy under nutritional stress conditions. Thus,
inhibition of mTORC1 leads to nuclear translocation of TFEB and
induction of the expression of autophagy genes [122].
Overall, the existence of diﬀerent transcriptional regulators of these
machineries also suggests crosstalk and partially redundant mechan-
isms that may assure proteostasis under diﬀerent circumstances.
Accordingly, NRF2 may have a relevant role in tissues that support
high levels of oxidative stress. For instance, oxidative stress-induced
NRF2 may function under nutrient-rich conditions to transcriptionally
up-regulate autophagy, similar to what has been found for TFEB under
starvation conditions. Moreover, the brain functions largely under
nutrient-rich conditions, posing NRF2 as a relevant mechanism to
activate autophagy in neurons.
7. Promising therapeutic potential for NRF2 in
proteinopathies
In the past few years, a great progress has been made in the
knowledge of the regulatory roles of the UPR, UPS and autophagy on
NRF2 activity, as well as the reciprocal NRF2-mediated transcription of
components of these three systems. Therefore, new therapeutic possi-
bilities may arise based on the exploitation of NRF2 as a crucial
regulator of protein clearance in neurodegenerative diseases.
However, a key remaining question is whether it will be useful or
deleterious to increase NRF2 levels in brain. Analysis of epidemiolo-
gical data may provide a partial answer, as it indicates that the NFE2L2
gene is highly polymorphic and some single nucleotide polymorphisms
found in its promoter regulatory region may provide a range of
“physiological” variability in gene expression at the population level
and some haplotypes were associated with decreased risk and/or
delayed onset of AD, PD or ALS [123]. Moreover, as discussed by
Hayes and colleagues [124], NRF2 eﬀect might have an U-shaped
response, meaning that too low NRF2 levels may result in a loss of
cytoprotection and increased susceptibility to stressors, while too much
NRF2 might disturb homeostatic balance towards a reductive scenario
(reductive stress), which would favor protein misfolding and aggrega-
tion. Low NRF2 levels in the brain support the idea that a slight up-
regulation may be suﬃcient to achieve a beneﬁt under pathological
conditions. In fact, the protective role of pharmacological NRF2-
mediated activation of protein clearance has been shown in diﬀerent
neurodegeneration cell culture and in vivo models.
SFN is a pharmacological NRF2 activator that was demonstrated to
induce proteasomal and autophagy gene expression [95,36].
Interestingly, Jo and colleagues demonstrated that SFN reduced the
levels of phosphorylated TAU and increased Beclin-1 and LC3-II,
suggesting NRF2 activation may facilitate degradation of this toxic
protein through autophagy [113]. Moreover, degradation of mHtt was
enhanced with SFN, and this was reverted with the use of MG132,
indicating proteasomal degradation of this toxic protein [95].
Autophagy-mediated degradation of phospho- and insoluble-TAU was
reported with the organic ﬂavonoid ﬁsetin. This compound was able to
induce autophagy by simultaneously promoting the activation and
nuclear translocation of both TFEB and NRF2, along with some of its
target genes. This response was prevented by TFEB or NRF2 silencing
[125]. Bott and colleagues reported beneﬁcial eﬀects of a simultaneous
NRF2, NRF1 and HSF1 activator on protein toxicity in spinal and
bulbar muscular atrophy, a neurodegenerative disorder caused by
expansion of polyglutamine-encoding CAG repeats in which protein
aggregates are present [126]. The potential of NRF2 activation for the
treatment of neurodegenerative disorders has been demonstrated with
the approval of BG-12, the oral formulation of the NRF2 inducer
dimethyl fumarate (DMF), for the treatment of multiple sclerosis
[127,128]. The success of DMF with autoimmune diseases with a
strong inﬂammatory component suggests that neurodegenerative dis-
eases might beneﬁt from repositioning this drug. In a recent preclinical
study of an α-synucleinopathy model of PD, DMF was shown to be
neuroprotective due, in part, to its induction of autophagy [129].
Studies reporting beneﬁcial eﬀects of NRF2 on neurodegeneration but
not focusing on its eﬀect on protein clearance are even more abundant
(for a comprehensive review, see [7]). This is quite relevant, as it
highlights the multiple damaging processes that can be simultaneously
targeted by a single hit in NRF2, also including oxidative stress,
neuroinﬂammation or mitochondrial dysfunction. However, future
work will be needed to deﬁnitely determine if pharmacological activa-
tion of NRF2 may be a valid strategy to facilitate degradation of toxic
proteins in the brain.
As explained before, exacerbated GSK-3β activity was reported in
neurodegenerative diseases and it has been speculated that consequent
NRF2 reduction can be partially responsible for the deleterious out-
come. Under these pathological conditions, GSK-3 inhibitors could also
cooperate to increase NRF2 levels and proteostasis. The beneﬁcial
eﬀects of GSK-3 inhibitors have been reported in diﬀerent models of
neurodegeneration and, more interesting, GSK-3 repression was shown
to reduce the levels of toxic proteins [130–133]. Although no direct
links between GSK-3 inhibition and NRF2-transcriptional regulation of
genes promoting proteostasis have been observed yet, it is reasonable
to speculate that down-regulation of GSK-3 activity would result in
increased NRF2 levels, which eventually will result in reinforced
proteostasis.
The transcriptional activity of NRF2 as well as the cellular capacity
to maintain proteostasis decrease with age, the main risk factor for the
development of neurodegenerative diseases. It is reasonable to think
that the reinforcement of NRF2 and, consequently, proteostasis would,
at least, delay the accumulation of protein aggregates and neurode-
generation. Indeed, treatment of human senescent ﬁbroblasts with
18α-glycyrrhetinic acid (18α-GA) triterpenoid promoted NRF2 activa-
tion, leading to proteasome induction and enhanced life span. This
study suggests that pharmacological activation of NRF2 is possible
even in late life [86]. Moreover, a later study showed that this
compound mediated SKN-1 and proteasome activation in C.elegans
with beneﬁcial eﬀects on AD progression in relevant nematode models
[134].
All things considered, NRF2-mediated induction of proteostasis-
related genes seems to be beneﬁcial in diﬀerent proteinopathies.
8. Concluding remarks
Transcription factor NRF2 orchestrates a proteostatic response by
sensing to and modulating changes in the UPR, UPS and autophagy
(Fig. 4). Consequently, the lack of NRF2 has been shown to aggravate
proteinopathy, suggesting that NRF2 is necessary for optimal protein
clearance. All together, we can speculate that NRF2 might be an
interesting therapeutic target for proteinopathies.
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